
Idexx Laboratories (IDXX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
998.4M
Gross Profit
623.4M
62.44%
Operating Income
316.5M
31.70%
Net Income
242.7M
24.31%
EPS (Diluted)
$2.96
Balance Sheet Metrics
Total Assets
3.2B
Total Liabilities
1.8B
Shareholders Equity
1.4B
Debt to Equity
1.22
Cash Flow Metrics
Operating Cash Flow
235.1M
Free Cash Flow
207.9M
Revenue & Profitability Trend
Idexx Laboratories Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 3.9B | 3.7B | 3.4B | 3.2B | 2.7B |
Cost of Goods Sold | 1.5B | 1.5B | 1.4B | 1.3B | 1.1B |
Gross Profit | 2.4B | 2.2B | 2.0B | 1.9B | 1.6B |
Gross Margin % | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% |
Operating Expenses | |||||
Research & Development | 219.8M | 191.0M | 254.8M | 161.0M | 141.2M |
Selling, General & Administrative | 1.0B | 901.9M | 850.8M | 796.4M | 735.3M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.3B | 1.1B | 1.1B | 957.4M | 876.5M |
Operating Income | 1.1B | 1.1B | 898.8M | 932.0M | 694.5M |
Operating Margin % | 29.0% | 30.0% | 26.7% | 29.0% | 25.7% |
Non-Operating Items | |||||
Interest Income | 12.7M | 5.6M | 1.1M | 434.0K | 586.0K |
Interest Expense | 31.2M | 41.6M | 39.9M | 29.8M | 33.1M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.1B | 1.1B | 860.0M | 902.7M | 662.0M |
Income Tax | 222.0M | 216.1M | 180.9M | 157.8M | 79.9M |
Effective Tax Rate % | 20.0% | 20.4% | 21.0% | 17.5% | 12.1% |
Net Income | 887.9M | 845.0M | 679.1M | 744.8M | 582.1M |
Net Margin % | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% |
Key Metrics | |||||
EBITDA | 1.3B | 1.2B | 1.0B | 1.0B | 791.1M |
EPS (Basic) | $10.77 | $10.17 | $8.12 | $8.74 | $6.82 |
EPS (Diluted) | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 |
Basic Shares Outstanding | 82467000 | 83066000 | 83623000 | 85200000 | 85342000 |
Diluted Shares Outstanding | 82467000 | 83066000 | 83623000 | 85200000 | 85342000 |
Income Statement Trend
Idexx Laboratories Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 288.3M | 453.9M | 112.5M | 144.5M | 383.9M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 473.6M | 457.4M | 400.6M | 368.3M | 331.4M |
Inventory | 381.9M | 380.3M | 367.8M | 269.0M | 209.9M |
Other Current Assets | 48.2M | 29.1M | 37.7M | 12.7M | 10.2M |
Total Current Assets | 1.4B | 1.5B | 1.1B | 955.7M | 1.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 116.1M | 115.5M | 118.6M | 105.1M | 91.2M |
Goodwill | 921.9M | 816.4M | 821.3M | 817.7M | 539.2M |
Intangible Assets | 111.7M | 84.5M | 97.7M | 99.0M | 52.5M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 489.8M | 440.3M | 362.2M | 311.8M | 277.5M |
Total Non-Current Assets | 1.9B | 1.8B | 1.6B | 1.5B | 1.2B |
Total Assets | 3.3B | 3.3B | 2.7B | 2.4B | 2.3B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 114.2M | 110.6M | 110.2M | 116.1M | 74.6M |
Short-term Debt | 439.3M | 344.8M | 674.4M | 168.4M | 67.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 1.1B | 951.5M | 1.2B | 763.6M | 582.8M |
Non-Current Liabilities | |||||
Long-term Debt | 547.6M | 722.6M | 795.6M | 862.6M | 935.5M |
Deferred Tax Liabilities | 11.3M | 7.2M | 8.2M | 8.9M | 11.7M |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 630.2M | 823.8M | 902.2M | 983.6M | 1.1B |
Total Liabilities | 1.7B | 1.8B | 2.1B | 1.7B | 1.7B |
Equity | |||||
Common Stock | 10.8M | 10.8M | 10.7M | 10.7M | 10.6M |
Retained Earnings | 5.3B | 4.4B | 3.6B | 2.9B | 2.2B |
Treasury Stock | 5.3B | 4.5B | 4.4B | 3.6B | 2.8B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.6B | 1.5B | 608.7M | 690.0M | 632.8M |
Key Metrics | |||||
Total Debt | 986.9M | 1.1B | 1.5B | 1.0B | 1.0B |
Working Capital | 332.0M | 543.7M | -134.3M | 192.1M | 480.0M |
Balance Sheet Composition
Idexx Laboratories Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 887.9M | 845.0M | 679.1M | 744.8M | 582.1M |
Depreciation & Amortization | 129.9M | 114.9M | 111.9M | 104.6M | 96.0M |
Stock-Based Compensation | 60.3M | 59.7M | 49.8M | 37.8M | 31.0M |
Working Capital Changes | -133.2M | -72.4M | -273.5M | -137.5M | -31.8M |
Operating Cash Flow | 921.9M | 899.5M | 534.8M | 748.9M | 640.6M |
Investing Activities | |||||
Capital Expenditures | -120.9M | -133.6M | -148.8M | -119.5M | -107.0M |
Acquisitions | -77.7M | 0 | -36.5M | -173.4M | -1.5M |
Investment Purchases | - | - | - | - | - |
Investment Sales | 1.6M | 8.4M | 0 | 0 | - |
Investing Cash Flow | -197.1M | -125.3M | -185.4M | -293.0M | -108.5M |
Financing Activities | |||||
Share Repurchases | -837.0M | -71.9M | -819.7M | -746.8M | -182.8M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | 0 | 0 | 200.0M |
Debt Repayment | -75.0M | -75.0M | -75.0M | -50.0M | 0 |
Financing Cash Flow | -922.6M | -489.0M | -406.7M | -744.0M | -299.7M |
Free Cash Flow | 798.1M | 772.9M | 384.1M | 636.0M | 540.2M |
Net Change in Cash | -197.7M | 285.2M | -57.2M | -288.0M | 232.4M |
Cash Flow Trend
Idexx Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
54.06
Forward P/E
54.42
Price to Book
35.76
Price to Sales
12.90
PEG Ratio
1.11
Profitability Ratios
Profit Margin
24.41%
Operating Margin
33.62%
Return on Equity
64.87%
Return on Assets
23.26%
Financial Health
Current Ratio
1.11
Debt to Equity
84.81
Beta
1.50
Per Share Data
EPS (TTM)
$12.04
Book Value per Share
$18.20
Revenue per Share
$49.56
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
idxx | 52.1B | 54.06 | 35.76 | 64.87% | 24.41% | 84.81 |
Thermo Fisher | 184.7B | 28.25 | 3.66 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Agilent Technologies | 33.9B | 29.36 | 5.52 | 18.88% | 17.59% | 60.04 |
Iqvia Holdings | 32.5B | 27.69 | 5.62 | 19.79% | 7.88% | 272.12 |
Mettler-Toledo | 27.0B | 33.22 | - | -680.23% | 21.46% | -8.44 |
Financial data is updated regularly. All figures are in the company's reporting currency.